BPC-157

Gastric Pentadecapeptide | Regenerative System

Technical card

System

Regenerative System
Type

Synthetic peptide — 15 amino acids
CAS

137525-51-0
Formula

C62H98N16O22
Mol. weight

1,419.53 Da
Form

Lyophilized vial
Purity

>98% by HPLC
Status

Active

View Research Library

Access to the catalog is structured — not open by default.

How Access Works Already have access? Sign In

Technical card

System

Regenerative System
Type

Synthetic peptide — 15 amino acids
CAS

137525-51-0
Formula

C62H98N16O22
Mol. weight

1,419.53 Da
Form

Lyophilized vial
Purity

>98% by HPLC
Status

Active

View Research Library

BPC-157 Overview

BPC-157 is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. Composed of 15 amino acids, it belongs to AXION’s Regenerative System — a research compound cluster organized around signaling pathways associated with tissue integrity and cellular repair. It has been the subject of over 130 peer-reviewed publications since the 1990s.

In preclinical models, BPC-157 is investigated for its activity across several interconnected signaling cascades, including the VEGFR2/eNOS angiogenic axis, the FAK-paxillin pathway in tendon fibroblasts, and ERK1/2-mediated transcription factor activation. The compound is described in the literature as pleiotropic: its downstream effects engage multiple biological systems simultaneously, and its primary binding receptor has not yet been identified.

Among peptides studied in research contexts, BPC-157 carries a notable biochemical characteristic: documented stability in acidic pH (2-3) for over 24 hours — atypical for bioactive peptides. This property is relevant to research models exploring non-parenteral administration routes, and distinguishes it from structurally similar compounds in the Regenerative System.

BPC-157 Research Directions

The published literature on BPC-157 spans more than three decades and multiple biological contexts. Below is an overview of the principal research areas documented in preclinical studies.

Musculoskeletal repair models — tendon, ligament, muscle, and bone physiology in rodent preparations
Gastrointestinal and mucosal protection — ulcer models, colitis, fistula resolution, NSAID- and alcohol-induced mucosal damage
Vascular function and angiogenesis — VEGFR2/eNOS axis, vasomotor tone regulation, ischemia/reperfusion contexts
Neuroprotection and CNS modulation — spinal cord injury models, ischemic stroke, dopaminergic system interactions
Tendon fibroblast migration — FAK-paxillin phosphorylation and extracellular matrix remodeling
Oral administration research — gastric acid stability (pH 2-3, >24 h) as a differentiating property for route-of-administration models
Growth hormone receptor potentiation — GHR upregulation in fibroblast models, JAK2 phosphorylation

Pathway

Description

VEGFR2 -> Akt -> eNOS

Promotes VEGFR2 upregulation and endocytosis in endothelial models, activating Akt and downstream eNOS-mediated nitric oxide production (VEGF-dependent).

Src -> Caveolin-1 -> eNOS

VEGF-independent pathway: Src and Cav-1 phosphorylation releases eNOS from its inhibitory complex in caveolae. Confirmed in isolated aortic tissue (Hsieh et al., 2020).

FAK -> Paxillin

Dose-dependent FAK and paxillin phosphorylation in rat tendon fibroblasts, promoting cell migration and ECM remodeling — without direct effect on basal proliferation.

ERK1/2 -> Egr-1

ERK1/2 activation in endothelial cells with upregulation of c-Fos, c-Jun, and Egr-1, regulating cell proliferation and vascular tube formation in vitro.

GHR upregulation

Dose- and time-dependent increase in GH receptor expression in tendon fibroblasts, potentiating GH response via JAK2 phosphorylation (Kuo et al., 2018).

Neurohumoral modulation

Documented interactions with dopaminergic, serotonergic, GABAergic, and prostaglandin systems in animal models. Bidirectional modulatory activity suggested.

The compound offered by AXION is a research-grade (RUO) version supplied exclusively for laboratory and research use. It is not related to, nor a substitute for, any approved pharmaceutical product. No therapeutic claim is made or implied.

BPC-157 Quality & Traceability

Every AXION compound is subject to analytical verification before release. Purity and traceability are not marketing attributes — they are part of the integrity of the research itself.

Certificate of Analysis

Available per lot on request.
Lot Traceability

Each vial carries a unique lot number linked to its full analytical record.
QR Verification

QR code on packaging links directly to the COA for that specific lot.
HPLC Verified

>98% purity per lot. Verified by HPLC + Mass Spectrometry.

Learn more about our verification process: Quality & Testing